ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET
Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Súhrn charakteristických
(SPC)
09-01-2013
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
IBUPROFEN; METHOCARBAMOL
Dostupné z:
TEVA CANADA LIMITED
ATC kód:
M03BA53
INN (Medzinárodný Name):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Dávkovanie:
200MG; 500MG
Forma lieku:
TABLET
Zloženie:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
Spôsob podávania:
ORAL
Počet v balení:
18/40
Typ predpisu:
OTC
Terapeutické oblasti:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Prehľad produktov:
Active ingredient group (AIG) number: 0248961001; AHFS:
Stav Autorizácia:
CANCELLED POST MARKET
Dátum Autorizácia:
2021-08-12
Súhrn charakteristických
1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................
Prečítajte si celý dokument
